qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer
Autor: | Xingmin Li, Wentao Yang, Ke Zuo, Xizi Liang, Xiangjie Sun, Xiaoying Yuan, Shujin Liu, Philip P. Connell |
---|---|
Rok vydání: | 2021 |
Předmět: |
Oncology
China Cancer Research medicine.medical_specialty Breast Neoplasms Triple Negative Breast Neoplasms Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols Biopsy medicine Humans Homologous Recombination Triple-negative breast cancer Platinum Retrospective Studies medicine.diagnostic_test business.industry Cancer Retrospective cohort study DNA Odds ratio medicine.disease Neoadjuvant Therapy Axilla Real-time polymerase chain reaction medicine.anatomical_structure Female business |
Zdroj: | Breast Cancer Research and Treatment. 191:335-344 |
ISSN: | 1573-7217 0167-6806 |
DOI: | 10.1007/s10549-021-06442-x |
Popis: | Cumulative evidence suggests that the addition of platinum agents as neoadjuvant chemotherapy (NACT) could improve the pathologic complete response (pCR) rate in triple-negative breast cancer (TNBC). We aimed to develop a DNA homologous recombination (HR)-associated gene expression score to predict tumor sensitivity to platinum-based NACT in TNBC. A retrospective cohort of 127 patients who were diagnosed with TNBC and received platinum-based NACT in Fudan University Shanghai Cancer Center from 2012 to 2017 was included in this study. Using quantitative reverse transcription-polymerase chain reaction (qRT-PCR), the expression levels of eight HR-associated genes were analyzed from formalin-fixed paraffin-embedded core-needle biopsy samples obtained before NACT. A random forest model was built to estimate the weight of each gene expression level and clinicopathological factors. The training set was used to modulate parameters and select the best model. The performance of the final model was evaluated in the validation set. A 4-gene (BRCA1, XRCC5, PARP1, and RAD51) scoring system was developed. TNBC patients with a higher score had a nearly fourfold likelihood of achieving pCR to platinum-based NACT compared with patients with a lower score [odds ratio (OR) = 3.878; P |
Databáze: | OpenAIRE |
Externí odkaz: |